TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸ABBV

AbbVie Inc. Common Stock

NYSE
$286.01
▲ $0.59 (+0.2%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 18 Nov 2026
H $302.93L $204.30+37.3%
$302.93$283.2$263.48$243.75$224.03$204.3$286.34
RSI (14)
Intraday · 15-minNeutral-5RSI 36DowntrendMACD Bullishfor day-trading context — not advice

Technical signal

Buy+35
RSI (14)49
oversold 30overbought 70
Trend
Uptrend
MACD
Bearish
Bollinger
Within bands
vs 20-day
below
vs 50-day
above
vs 200-day
above
Support
$278.01
Resistance
$302.93
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2026-02-17 → 2026-11-18

Strategy return
+31.5%
Buy & hold
+23.0%
Trades
2
Win rate
50%

$100,000.00 invested would be worth $131,509.63 (+31.5%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About AbbVie Inc.· Drug Manufacturers - General

source: yahoo

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
57,000
Headquarters
North Chicago, United States
www.abbvie.com ↗

Fundamentals

source: yahoo
Market cap
$505.89B
P/E
49.2
P/B
—
EPS
$5.82
Div yield
2.4%
Profit margin
15.7%
ROE
—
Debt / Equity
—
Beta
0.19
52-week range
$190.75 – $302.93
52-week low · $190.7585% of rangehigh · $302.93

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive4↑ · 0↓ · 4–
  • Is Lilly Stock's Winning Streak Skill Or Luck?— Neutral
    Trefis · 18 Nov 2026
  • Invest $100,000 in These 4 Dividend Stocks and Collect Passive Income for Life▲ Positive
    24/7 Wall St. · 18 Nov 2026
  • Bristol Myers Stock's Dividends Couldn't Close The Gap— Neutral
    Trefis · 18 Nov 2026
  • What Drove Glaukos Stock's 48% Rally Since the End of September?

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

▲ Positive
Zacks · 18 Nov 2026
  • Johnson & Johnson vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?▲ Positive
    Motley Fool · 17 Nov 2026
  • How Did AbbVie's Neuroscience Franchise Perform in Q3?— Neutral
    Zacks · 17 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.